BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:QLC7401 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of QLC7401\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07444086-1055@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271007
DTEND;VALUE=DATE:20271008
SUMMARY:QLC7401: Phase 3 readout est. (NCT07444086)
DESCRIPTION:QLC7401\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dys
 lipidemia\nEstimated primary completion: 7 October 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/qlc7401#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07444086
URL:https://assetmemo.bio/drug/qlc7401#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441317-1055@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:QLC7401: Phase 3 readout est. (NCT07441317)
DESCRIPTION:QLC7401\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyp
 erlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)\nEst
 imated primary completion: December 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/qlc7401#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07441317
URL:https://assetmemo.bio/drug/qlc7401#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07450378-1055@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:QLC7401: Phase 3 readout est. (NCT07450378)
DESCRIPTION:QLC7401\, phase 3\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: QLC7401 in Participants With Heterozygous Familial Hypercholesterolem
 ia (HeFH)\nEstimated primary completion: April 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/qlc7401#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07450378
URL:https://assetmemo.bio/drug/qlc7401#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
